ALTERITY THERAPEUTICS LTD (ATHE) SEC Filings, Jul-Aug 2025

Alterity Therapeutics (ATHE) is a development‑stage biopharmaceutical group focused on neurodegenerative diseases, notably ATH434 for Multiple System Atrophy (MSA). The company reported a net loss of A$12.15 million for the year and recorded a A$5.44 million R&D tax incentive as other income. Cash and cash equivalents increased to A$33.16 million at June 30, 2025, supported by significant equity raises including a placement of 3.636 billion shares at A$0.011 and issuance of 1.222 billion listed long‑dated options. Multiple patents (including composition of matter for ATH434) have been granted in several jurisdictions; one U.S. patent lists expiry June 7, 2026. Clinical and conference activity in 2024–2025 includes Phase 2 ATH434 data presented at major neurology meetings. The company continues to disclose material risks: ongoing operating losses, need for further financing, clinical development and manufacturing risks, intellectual property challenges, and NASDAQ listing and PFIC considerations.